Book a Meeting

Anti-Human DAF Monoclonal Antibody (clone 1C6) -10 mg (CAT#: CB-P459-K) Datasheet

Product Type
The monoclonal antibody 1C6 recognizes human complement decay accelerating factor (DAF), also known as CD55. Cells express several proteins on their surface that protect against complement attack, namely complement receptor I (CR1), decay accelerating factor (DAF), Membrane cofactor protein (MCP) and CD59. CR1, DAF and MCP regulate the activation pathway of complement by accelerating the decay of C3 and C5 convertase (CR1, DAF) or acting as a cofactor for serine protease I. The cleavage of this factor is irreversible Inactivate C3b (CR1, MCP).
Human DAF (CD55) is a 381 amino acid protein that produces a transmembrane protein of about 60 kDa, which binds to C3b and C4b, thereby inhibiting the formation and half-life of C3 convertase. It belongs to the complement activation (RCA) family of receptors. DAF is widely distributed in cells in contact with plasma complement proteins, including hematopoietic and non-hematopoietic cells. Although DAF has no important role in controlling hemolysis of red blood cells, it plays an important role in regulating the deposition of C3 on nucleated cells.
DAF works with other complement regulators to protect one's own cells from damage mediated by autologous complement. DAF and CD46 together prevent the deposition of autologous C3, while CD59 inhibits this pathway at a key endpoint. DAF is overexpressed in some tumors, thereby limiting the complement-dependent cytotoxicity of therapeutic anti-cancer antibodies. Combining with cancer immunotherapeutic monoclonal antibodies using DAF blocking antibodies specifically targeting cancer cells can improve the therapeutic effect on cancer patients.
100 µg

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *